Pasithea Therapeutics Corp. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KTTA Nasdaq 2836 www.pasithea.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pasithea Therapeutics Corp.

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Jan 13th, 2026 5:01 am
Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10% - Dec 4th, 2025 3:58 am
Lawrence Steinman Bought 201% More Shares In Pasithea Therapeutics - Dec 4th, 2025 3:53 am
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - Dec 2nd, 2025 5:00 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Dec 1st, 2025 6:38 am
US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong - Nov 28th, 2025 11:52 am
BC-Most Active Stocks - Nov 28th, 2025 8:30 am
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - Nov 28th, 2025 7:20 am
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS - Nov 25th, 2025 5:00 am
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - Nov 24th, 2025 5:00 am
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - Nov 21st, 2025 10:35 am
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Nov 20th, 2025 2:01 pm
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients - Nov 4th, 2025 5:03 am
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients - Sep 16th, 2025 5:03 am
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Sep 8th, 2025 5:01 am
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Aug 29th, 2025 6:39 am
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Aug 28th, 2025 5:02 am
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Jul 31st, 2025 5:01 am
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board - Jun 11th, 2025 5:02 am
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 - Jun 2nd, 2025 6:02 am